Please login to the form below

Not currently logged in
Email:
Password:

Abbott and AstraZeneca co-promote Trilipix

Abbott and AstraZeneca have entered into an agreement for the co-promotion of Abbott's lipid disorder treatment, Trilipix

Abbott and AstraZeneca have entered into an agreement for the co-promotion of Abbott's lipid disorder treatment, Trilipix.

Under the terms of the agreement, AstraZeneca will gain non-exclusive rights to co-promote Trilipix in the US, excluding Puerto Rico.

Trilipix is used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. It is also used in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol.

"Abbott's portfolio of lipid therapies is designed to help physicians manage a patient's total lipid profile," said Jeffrey Stewart, divisional vice president, primary care, Abbott. "With AstraZeneca's established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of Trilipix among physicians whose patients may benefit from this medication."

Jim Helm, vice president, cardiovascular, AstraZeneca US, said: "With clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, Trilipix is another important therapeutic option we can now offer physicians."

This is the second co-promotion deal between the two pharmaceutical companies. In August 2008 they signed a non-exclusive deal for the co-promotion of AstraZeneca's Crestor in the US market. Specific financial terms of the Trilipix deal were not disclosed.

4th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics